/TNDM
TNDM Stock - Tandem Diabetes Care, Inc.
Healthcare|Medical - DevicesNASDAQ
$22.07+1.24%
+$0.27 (+1.24%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.92
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).82
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.52
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+15.9%upside
Target: $25.58
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TNDM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$21.85 – $22.29
TARGET (TP)$25.57
STOP LOSS$20.30
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.69
52W High$38.28
52W Low$9.98
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $940.20M | $747.72M | $801.22M | $702.80M | $498.83M |
| Gross Profit | $489.57M | $367.69M | $412.99M | $376.21M | $260.52M |
| Gross Margin | 52.1% | 49.2% | 51.5% | 53.5% | 52.2% |
| Operating Income | $-99,127,000 | $-233,230,000 | $-92,848,000 | $22.65M | $-7,957,000 |
| Net Income | $-96,025,000 | $-222,611,000 | $-94,594,000 | $15.57M | $-34,382,000 |
| Net Margin | -10.2% | -29.8% | -11.8% | 2.2% | -6.9% |
| EPS | $-1.47 | $-3.43 | $-1.47 | $0.25 | $-0.56 |
Company Overview
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
40%
Hold / Neutral
13
52%
Sell / Underperform
2
8%
Analyst Consensus🔴 Bearish
10 Bullish15 Neutral/Bearish
Price Targets
$38
Average Target
↑ 72.1% Upside
Now
$10
Low
$38
Average
$75
High
Based on 30 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 16th 2025 | Robert W. Baird | Upgrade | Outperform | $30 |
| October 21st 2025 | Stifel | Resumed | Hold | $15 |
| September 8th 2025 | Oppenheimer | Initiation | Outperform | $22 |
| August 12th 2025 | Citigroup | Upgrade | Neutral | $10.35 |
| August 7th 2025 | Piper Sandler | Downgrade | Neutral | $14 |
| July 9th 2025 | Citigroup | Downgrade | Sell | $14 |
| June 16th 2025 | Truist | Initiation | Hold | $24 |
| April 10th 2025 | Mizuho | Initiation | Neutral | $20 |
| March 5th 2025 | Morgan Stanley | Downgrade | Equal Weight | $22← $45 |
| March 4th 2025 | Citigroup | Downgrade | Neutral | $24← $35 |
| March 3rd 2025 | Wells Fargo | Downgrade | Equal Weight | $22← $38 |
| February 28th 2025 | Bernstein | Downgrade | Market Perform | $25← $35 |
| December 2nd 2024 | Morgan Stanley | Upgrade | Overweight | $45 |
| November 6th 2024 | Bernstein | Initiation | Outperform | $42 |
| October 4th 2024 | Goldman | Initiation | Neutral | $46 |
Earnings History & Surprises
TNDMBeat Rate
33%
Last 18 quarters
Avg Surprise
-129.6%
EPS vs Estimate
Beats / Misses
6/11
1 met exactly
Latest EPS
$-0.31
Q4 2025
EPS Surprise History
Q1 24
-17.4%
$-0.27vs$-0.23
Q2 24
+21.3%
$-0.63vs$-0.80
Q3 24
+13.0%
$-0.47vs$-0.54
Q4 24
+16.3%
$-0.36vs$-0.43
Q1 25
-76.0%
$-0.44vs$-0.25
Q2 25
-11.7%
$-0.67vs$-0.60
Q3 25
-20.0%
$-0.48vs$-0.40
Q4 25
0.0%
$-0.31vs$-0.31
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.06 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.31 | $-0.31 | 0.0% | = MET |
Q3 2025 | Aug 6, 2025 | $-0.40 | $-0.48 | -20.0% | ✗ MISS |
Q2 2025 | Apr 30, 2025 | $-0.60 | $-0.67 | -11.7% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $-0.25 | $-0.44 | -76.0% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.43 | $-0.36 | +16.3% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-0.54 | $-0.47 | +13.0% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.80 | $-0.63 | +21.3% | ✓ BEAT |
Q1 2024 | Feb 21, 2024 | $-0.23 | $-0.27 | -17.4% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $-0.35 | $-0.38 | -8.6% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-0.54 | $-0.30 | +44.4% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.56 | $-0.63 | -12.5% | ✗ MISS |
Q1 2023 | Feb 22, 2023 | $-0.00 | $-0.01 | -338.6% | ✗ MISS |
Q4 2022 | Nov 2, 2022 | $-0.05 | $-0.27 | -455.3% | ✗ MISS |
Q3 2022 | Aug 3, 2022 | $-0.02 | $-0.24 | -1460.5% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-0.07 | $-0.23 | -228.6% | ✗ MISS |
Q1 2022 | Feb 22, 2022 | $0.21 | $0.16 | -23.8% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $0.06 | $0.09 | +50.0% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $-0.08 | $0.06 | +175.0% | ✓ BEAT |
Latest News
Truist Securities Maintains Hold on Tandem Diabetes Care, Raises Price Target to $24
➖ NeutralBenzinga•Dec 18, 2025, 04:03 PM
Canaccord Genuity Maintains Buy on Tandem Diabetes Care, Raises Price Target to $35
📈 PositiveBenzinga•Dec 17, 2025, 08:12 PM•Also:
Mizuho Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $21
➖ NeutralBenzinga•Dec 17, 2025, 01:10 PM
Tandem Diabetes Care shares are trading higher after Baird upgraded the stock from Neutral to Outperform and raised its price target from $18 to $30.
📈 PositiveBenzinga•Dec 16, 2025, 02:15 PM
Baird Upgrades Tandem Diabetes Care to Outperform, Raises Price Target to $30
📈 PositiveBenzinga•Dec 16, 2025, 11:25 AM
Citigroup Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $22
📈 PositiveBenzinga•Dec 11, 2025, 08:58 PM•Also:
Morgan Stanley Maintains Equal-Weight on Tandem Diabetes Care, Raises Price Target to $23
➖ NeutralBenzinga•Dec 2, 2025, 05:59 PM
Barclays Maintains Overweight on Tandem Diabetes Care, Raises Price Target to $55
📈 PositiveBenzinga•Nov 10, 2025, 07:25 PM•Also:
Morgan Stanley Maintains Equal-Weight on Tandem Diabetes Care, Raises Price Target to $17
📈 PositiveBenzinga•Nov 10, 2025, 06:14 PM
Truist Securities Reiterates Hold on Tandem Diabetes Care, Raises Price Target to $17
➖ NeutralBenzinga•Nov 10, 2025, 05:07 PM
Tandem Mobi App For Android Receives FDA Clearance
📈 PositiveBenzinga•Nov 10, 2025, 01:38 PM
Wells Fargo Maintains Equal-Weight on Tandem Diabetes Care, Raises Price Target to $14
📈 PositiveBenzinga•Nov 7, 2025, 06:46 PM
Tandem Diabetes Care shares are trading higher after the company reported better-than-expected Q3 sales results and issued FY25 sales guidance above estimates.
📈 PositiveBenzinga•Nov 7, 2025, 11:57 AM
Tandem Diabetes Care soars after double Q3 beats
📈 PositiveSeeking Alpha•Nov 6, 2025, 11:06 PM
Tandem Diabetes Care shares are trading higher after the company reported better-than-expected Q3 sales results and issued FY25 sales guidance above estimates.
📈 PositiveBenzinga•Nov 6, 2025, 09:49 PM
Tandem Diabetes Care GAAP EPS of -$0.31 beats by $0.05, revenue of $249.25M beats by $13.48M
📈 PositiveSeeking Alpha•Nov 6, 2025, 09:37 PM
Tandem Diabetes Care Affirms FY2025 Sales Guidance of $1.000B vs $998.025M Est
📈 PositiveBenzinga•Nov 6, 2025, 09:10 PM
Tandem Diabetes Care Q3 Adj. EPS $(0.31), Inline, Sales $249.253M Beat $236.963M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 09:09 PM
Tandem Diabetes Care Achieves ISO/IEC 27001:2022 Certification From Insight Assurance
📈 PositiveBenzinga•Nov 4, 2025, 01:35 PM
Tandem Diabetes Care Announces That Its t:slim X2 Insulin Pump With Control-IQ+ Automated Insulin Delivery Now Integrates With Abbott's Freestyle Libre 3 Plus CGM In The U.S.
📈 PositiveBenzinga•Oct 29, 2025, 12:38 PM•Also:
Frequently Asked Questions about TNDM
What is TNDM's current stock price?
Tandem Diabetes Care, Inc. (TNDM) is currently trading at $22.07 per share. The stock has moved +1.24% today.
What is the analyst price target for TNDM?
The average analyst price target for TNDM is $25.57, based on 1 analyst.
What sector is Tandem Diabetes Care, Inc. in?
Tandem Diabetes Care, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is TNDM's market cap?
Tandem Diabetes Care, Inc. has a market capitalization of $1.50 billion, making it a small-cap company.
Does TNDM pay dividends?
No, Tandem Diabetes Care, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorEYPT
EyePoint Pharmaceuticals, Inc.
$17.43
Mkt Cap: $1.2B
FTRE
Fortrea Holdings Inc.
$17.74
Mkt Cap: $1.6B
IART
Integra LifeSciences Holdings Corporation
$12.65
Mkt Cap: $1.0B
INMD
InMode Ltd.
$14.36
Mkt Cap: $1.0B
KOD
Kodiak Sciences Inc.
$26.00
Mkt Cap: $1.4B
NRIX
Nurix Therapeutics, Inc.
$18.52
Mkt Cap: $1.4B
PHAT
Phathom Pharmaceuticals, Inc.
$17.53
Mkt Cap: $1.2B
SEPN
Septerna, Inc.
$29.58
Mkt Cap: $1.3B
TNGX
Tango Therapeutics, Inc.
$8.52
Mkt Cap: $0.9B
URGN
UroGen Pharma Ltd.
$22.80
Mkt Cap: $1.1B
Explore stocks similar to TNDM for comparison